In 2018, instead of recommending PSA tests for specific populations, the USPSTF recommended selectively offering or providing screening for the early detection of prostate cancer to patients, based on clinicians’ judgment and patient preferences, and called for shared decision-making about the benefits and harms of PSA-based screening between clinicians and all men ages of 55 and 69 years old, and especially between clinicians and men among high-risk groups, such as African American men (AAM) and men with a family history of prostate cancer [2]. This evidence concerns the gene KLK3 and Familial prostate cancer.